Evidence & regulatory context
- Mechanism
- Murine serpin protein; no ChEMBL entity queried as no defined chemical entity exists. ClinicalTrials.gov searched for Serpina3n and the human orthologue term alpha-1-antichymotrypsin: all 5 returned records were unrelated behavioural and allergic-rhinitis studies matching on the token 'act', all rejected. Zero trials is a deliberate filtered decision.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundC57BLKS/J background, homozygous (diabetic) or heterozygous (non-diabetic littermate) for the spontaneous leptin receptor mutationMalen = At day 18, n=14 SA3N-treated and n=17 vehicle-treated anima…Topical injection under the Tegaderm for the first four treatments, then subcutaneous injection around the wound from day 12Reported in the full text as 35 ng per unit volume diluted…Immediately after wounding
Model: Full-thickness excisional dorsal skin wound in genetically induced type II diabetic mice, 10 mm punch biopsy outline with full-thickness excision including the panniculus carnosus, covered with Tegaderm
Serpina3n accelerated diabetic wound closure from day 12 onwards with greater re-epithelialisation and contraction, more mature granulation tissue, increased proliferation, vascularisation, myofibroblast content and collagen deposition, and preserved full-length fibronectin.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.